Vasculitis & polymyalgia rheumatica
Comparative Efficacy of Secukinumab Versus Tumor Necrosis Factor Inhibitors for the Treatment of Takayasu Arteritis
Authors' conclusion
Our findings suggest that secukinumab and TNFi are effective for patients with TAK who do not respond to oral glucocorticoids and conventional immunosuppressive agents, with similar response rates at 3 and 6 months.
Study context
- Population
- Patients with active TAK not responding to GC combined with 2 immunosuppressive agents
- Participants
- 19 vs 34
- Exposure
- Secukinumab vs TNF inhibitors (TNFi) as add-on therapy without increased GC dosage
- Secukinumabn = 19
- TNFin = 34reference
- Outcome
- Complete and partial response (complete: resolution of signs and symptoms of active disease, normal inflammatory markers, no imaging progression, GC <15 mg/day; partial: as complete except ESR <40 mm/hour and CRP <20 mg/liter)
- Follow-up
- 3 and 6 months
Methodological detailssingle-centre, open-label
- Single-centre
- Open-label
Main finding
As reported in the abstract
Complete and partial response · 3 months
P = 0.057
Observational data: associations, not effects.
Further findings
Complete and partial response · 6 months
P = 0.389
Original publication
Comparative Efficacy of Secukinumab Versus Tumor Necrosis Factor Inhibitors for the Treatment of Takayasu Arteritis. Arthritis Rheumatol. Published 8 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →